BIVDA Press Releases

Jan 21, 2021
Cardiff, UK – 21st January 2021 – EKF Diagnostics, the global in vitro diagnostics company, announces that it has expanded into new larger manufacturing facilities at Llandough Trading Estate, Cardiff, to increase production of PrimeStore® MTM viral transport media, a key component for the COVID-19 testing regime. The new facility is over 600 sq. metres, representing a 100% increase in manufacturing area. This enables EKF to fill 36,000 PrimeStore MTM tubes daily and meet gr...
Read More
Jan 14, 2021
Member Press Release – New England Biolabs Multiplex Assay KitThis new research use only kit enables high throughput multiplex detection of SARS-CoV-2 nucleic acid, supports increased sample input and reduces background amplification from possible contaminating genomic DNA. IPSWICH, MA (January 12, 2021) — New England Biolabs® (NEB®) today announced the launch of its Luna® SARS-CoV-2 RT-qPCR Multiplex Assay Kit for real-time detection of SARS-CoV-2 nuc...
Read More
Jan 11, 2021
BIVDA Statement on UK Rare Disease Framework BIVDA Chief Executive Doris-Ann Williams has welcomed the publication of the UK Rare Diseases Framework. The Framework lists the priorities and underlying strategic themes that detail how the UK will address the challenges faced by those living with rare diseases, with four high-level priorities for action over the next five years: Helping patients get a final diagnosis faster; increasing awareness of rare diseases among healthcare professio...
Read More
Jan 07, 2021
BIVDA represents the industry sector who manufacture and distribute diagnostic tests to the NHS. These rely on a high level of automation and so industry has service engineers and technical specialists working in NHS pathology laboratories alongside NHS staff to ensure that the equipment is maintained and allowing diagnostic test results to be issued without delay.  Doris-Ann Williams, BIVDA’s Chief Executive said “This equipment will have been subjected to infected samples and ...
Read More
Dec 23, 2020
BIVDA has issued a Press Release on the MHRA's decision to grant exceptional use authorisation for NHS Test and Trace's self-testing device.  BIVDA Chief Operating Officer – Helen Dent said; “We welcome the exceptional use authorisation for this self-test device to be used as part of the wider strategy to test for and control COVID-19, but emphasise that this is part of the solution and other methods and laboratory tests remain vital. This technology has a...
Read More
Dec 21, 2020
A short statement has been released by BIVDA’s Chief Operating Officer Helen Dent on the COVID-19 border closures.  Helen said; “Similarly to pharmaceutical companies, BIVDA members have planned contingencies in place for border emergencies in line with business continuity planning, which includes buffer stock and the ability to re-route supplies. Therefore, the provision of Diagnostic testing supplies will continue. We continue to monitor events and suppliers are working w...
Read More
Dec 16, 2020
LEX Diagnostics is developing a point-of-care PCR platform that is a major improvement in speed, cost and ease-of-use over all existing molecular diagnostics in the market today. Originally designed as an influenza & RSV platform specifically for use in primary care, LEX is playing its part in getting us through the current Covid pandemic with a combined flu/Covid test providing an answer in around 5 minutes – even for low viral load samples. The entire process from swab elution throug...
Read More
Dec 02, 2020
 BIVDA Chief Executive Doris-Ann Williams has welcomed the confirmation of the first COVID-19 vaccine to be approved by British regulators. Doris-Ann said; “We are delighted that the MHRA have approved the Pfizer/BioNTech coronavirus vaccine for widespread use, meaning it can start its roll out from next week. On behalf of BIVDA and the in vitro diagnostics sector, I would like to congratulate all those involved in this incredible scientific achievement.  An effective v...
Read More
Nov 30, 2020
BIVDA Chief Executive Doris-Ann Williams has commented on the launch of the Medicines and Diagnostic Manufacturing Transformation Fund. “We welcome the announcement of the Medicines and Diagnostic Manufacturing Transformation Fund by the Prime Minister today.  The lessons the country has learned during this difficult year in pandemic response must not be forgotten, and the innovations should be used to improve our diagnostic testing system for non-COVID illnesses including cancer...
Read More
Nov 25, 2020
BIVDA Comments on Spending Review 2020 BIVDA has commented on Chancellor Rishi Sunak’s speech to the House of Commons, where he announced the results of the 2020 Spending Review. Outlining measures designed to help the NHS maintain services as it recovers from the ongoing pandemic, the Chancellor announced £3 billion for recovery projects, including enhanced diagnostic testing, and greater capital spending to help replace outdated diagnostics equipment in hospitals. The NHS budg...
Read More
Page 5 of 12 [5]